InforSense Expands Ongoing Collaboration With AstraZeneca

InforSense Ltd, the leader in integrative analytics platforms, today announced that AstraZeneca (NYSE, LSE, SSE: AZN) has strengthened their strategic commitment to InforSense technology across their research and development organization through a new multi-year global licensing deal. Scientists at AstraZeneca R&D sites will use InforSense’s workflow-based integrative analytics environment, InforSense® KDE, to derive research intelligence and enhance productivity in their core drug discovery programs. Financial terms of the agreement were not disclosed.

MORE ON THIS TOPIC